| Literature DB >> 15571213 |
K Komoriya1, S Hoshide, K Takeda, H Kobayashi, J Kubo, M Tsuchimoto, T Nakachi, H Yamanaka, N Kamatani.
Abstract
The diurnal change of sUA and the effect of febuxostat on this change were investigated in 10 patients with gout and/or hyperuricemia. The diurnal sUA change after the last dose during the 4-week treatment phase (20 mg, QD) was almost the same as the pre-treatment value. Considering the dose, the AUC(obs) and Cmax of unchanged drug in patients with gout and/or hyperuricemia were estimated to be similar to those of healthy male adults. The results show that a 6-week treatment with febuxostat is safe and well-tolerated in the target patient population for this drug.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15571213 DOI： 10.1081/NCN-200027381
Source DB: PubMed Journal: Nucleosides Nucleotides Nucleic Acids ISSN： 1525-7770 Impact factor: 1.381